Additional 3.65 million euro to Taaleri from Ratiperä wind farm

TAALERI PLC                                 STOCK EXCHANGE RELEASE   29.6.2018  

Additional 3.65 million euro to Taaleri from Ratiperä wind farm

Taaleri records an additional selling price from the Ratiperä wind farm, sold in 2016. The wind farm located in Jämijärvi, Finland was a wind power project developed by Taaleri. Under the terms of the deal, Taaleri was entitled to an additional selling price, if certain conditions were met.

Taaleri Oyj records a profit of approximately EUR 3.65 million in the half year report 2018.

Taaleri’s long-term financial targets remain unchanged.

Taaleri Plc
Communications

Addtional information:

Juhani Elomaa, Managing Director, Taaleri Plc, +358 40 778 9020, juhani.elomaa@taaleri.com

Taaleri in brief

Taaleri is a Finnish financial service company, whose parent company Taaleri Plc is listed on Nasdaq Helsinki's main market. The Taaleri Group comprises three business areas: Wealth Management, Financing, and Energy. Taaleri provides services to institutional investors, companies and private individuals. The Group’s operational subsidiaries are: Taaleri Wealth Management Ltd and its subsidiaries, Taaleri Private Equity Funds Group, Taaleri Investments Group, Taaleri Energia Oy Group and Garantia Insurance Company Ltd. In addition, Taaleri has associated companies Fellow Finance Plc, which offers peer-to-peer lending services and Ficolo Oy developing data centers.

At the end of December 2017, Taaleri had assets under management totaling 5.6 billion euro and 4,400 wealth management customers. Taaleri Plc has some 3,900 shareholders. Taaleri's operations are supervised by the Finnish Financial Supervisory Authority.

More information about our company and services: 

www.taaleri.com/en
www.fellowfinance.fi/en
www.garantia.fi/en

Sophie Jolly, Head of Communications and IR, sophie.jolly@taaleri.com, tel. +358 40 828 7317

© 2018 GlobeNewswire, Inc. All Rights Reserved.

Read More..

The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.

FSD Pharma (Nasdaq: HUGE) Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis